

PROGRAM

PROGRAMME

1. međunarodni

KONGRES

ONKOLOGA I HEMATOLOGA

1st international CONGRESS

OF ONCOLOGISTS AND HEMATOLOGISTS

24-26.

OKTOBAR / OCTOBER
2024.

BUDVA

MONTENEGRO
CRNA GORA

organizator / organizer:



CRNOGORSKO UDRUŽENJE ONKOLOGA I HEMATOLOGA
MONTENEGRIN ASSOCIATION OF ONCOLOGISTS AND HEMATOLOGISTS



DEUTSCHE GESELLSCHAFT FÜR
HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE



European Board for Accreditation in Hematology



Uz podršku Njemačkog društva hematologa i onkologa.
With the support of German Society of Hematology and Medical Oncology.

1. međunarodni

KONGRES

ONKOLOGA I HEMATOLOGA

1st international CONGRESS

OF **ONCOLOGISTS** AND **HEMATOLOGISTS**

**PREDSJEDNIK KONGRESA
PRESIDENT OF CONGRESS**

Milena Dapčević

**PREDSJEDNIK NAUČNOG ODBORA
PRESIDENT OF THE SCIENTIFIC COMMITTEE**

Nadežda Basara

**NAUČNI ODBOR
SCIENTIFIC COMMITTEE**

Nadežda Basara

Milena Dapčević

Vanja Karađinović

Marija Stolić

Dijana Šišević

Carsten Bokemeyer

Konstanze Doehner

**ORGANIZACIONI ODBOR
ORGANIZING COMMITTEE**

Dijana Šišević

Milena Dapčević

Budva, oktobar 2024.

Prvi dan kongresa / First day of the Congress / 24.10.2024

15:00 Svečano otvaranje Kongresa / Opening ceremony

Predsjednica ljekarske komore Crne Gore / President of the Medical Chamber of Montenegro
Dr. med. Žanka Cerović

Sesija 1 / Session 1

15:10-16:50 Šta je novo u dijagnostici i terapiji hematoloških bolesti?

Šta izabrani ljekar treba da zna?

What's new in the diagnosis and therapy of hematologic diseases?

What should the primary physician know?

Moderatori/Moderators: Nadežda Basara, Milena Dapčević

15:10-16:00 Nada Suvajdžić-Vuković (Srbija/Serbia)

Imunološka trombocitopenija odraslih: dijagnostika i terapija

Immune thrombocytopenia in adults: diagnostic and treatment

16:10-16:30 Irina Panovska-Stavridis (Sjeverna Makedonija/North Macedonia)

Trombociti preko 600? Šta uraditi? / Thrombocytes over 600? How to manage?

16:30-16:50 Ana Vidović (Srbija/Serbia)

Acute myeloid leukemia: izlečiva bolest? / Acute leukemia: a curable disease?

17:00-17:30 Kafe Pauza / Coffee break

Simpozijum / Symposium

17:30-18:00 Vemax Pharma

Milena Dapčević: Nove terapijske mogućnosti u tretmanu anemije i polineuropatije
New treatment of anemia and polyneuropathy

Simpozijum / Symposium

18:00-18:45 Novartis

Dijana Šišević, Milena Dapčević:

Mjesto lijeka Scemblix (asciminib) u terapiji hronične mijeloidne leukemije

The Role of Scemblix (asciminib) in the Treatment of Chronic Myeloid Leukemia

Sesija 2 / Session 2

18:45-19:45 Forum za pacijente / Forum for Patients

Onkološka rehabilitacija / Oncological rehabilitation

Moderator: Dijana Šišević

18:45-19:05 Vesna Bokan-Mirković (Crna Gora/Montenegro)

Onkološka rehabilitacija: Preporuke

Oncological rehabilitations: recommendations

19:05-19:25 Damira Murić (Crna Gora/Montenegro)

Šta je važno za psihu? / What is important for the Psyche?

19:25-19:45 Snežana Barjaktarović-Labović (Crna Gora/Montenegro)

Šta je važno da znate o ishrani? / What is important to know about nutrition?

Simposium / Symposium

9:00-09:30 Astra Zeneka

Olivera Bošković, Danilo Radunović, Milena Dapčević:

Kompleksnost u dijagnostici i liječenju rijetkih bolesti

Complexity in diagnosis and treatment of rare disease-ULTOMIRIS CASE

Sesija 3 / Session 3

9:30-11:00 Joint CUOH-EHA Session:

Limfoproliferativne bolesti / Lymphoproliferative disorders

Moderatori: Predsjednica CUOH-a, Milena Dapčević i Predsjednik-izabrani EHA, Konstanze Doehner

Chair: President of CUOH, Milena Dapčević and President-elect of EHA, Konstanze Doehner

09:30-10:00 Angela Krackhardt (Njemačka/Germany)

Visoko rizični limfomi / High grade Lymphoma

10:00-10:30 Ronald Repp (Njemačka/Germany)

Multipli mijelom / Multiple Myeloma

10:30-11:00 Christian Buske (Njemačka/Germany)

Nisko rizični limfomi i CLL / Low risk Lymphoma and CLL

11:00-11:30 Kaffe Pauza / Coffee break

Simpozijum / Symposium

11:30-12:30 Roche

Napredak u terapiji DLBCL i SCLC

Redefining survival: Latest Advances in DLBCL and SCLC Therapies

Predavači / Speakers: **Dijana Šišević, Vanja Karađinović**

Moderatori/Moderators: Milena Dapčević, Ana Vukičević Delić

Sesija 4 / Session 4

**12:30-14:00 Nova saznanja o limfoproliferativnim bolestima:
dijagnostički i terapijski izazovi**

New insights in lymphoproliferative disorders:

Diagnostic and therapeutic challenges

Moderatori/Moderators: Angela Krackhardt, Ronald Repp

12:30-13:00 Nadežda Basara (Njemačka/Germany)

Hodgkin Limfom: kako lečiti? / Hodgkin Lymphoma: how to treat?

13:00-13:30 Filip Vukmirović (Crna Gora/Montenegro)

Primarni mediastinalni limfom: kako dijagnostikovati?

Primary mediastinal Lymphoma: How to make a diagnosis?

13:30-13:50 Jelena Bila (Srbija/Serbia)

Amiloidoza: Up to Date 2024 / Amyloidosis: Up to Date 2024

13:50-14:20 Ručak / Lunch

14:20 - 14:30 Otvaranje DGHO / Opening of the DGHO part of the Congress

Njegova ekscelencija Ambasador Njemačke u Crnoj Gori, **Peter Felten**
His Excellency Ambassador of Germany in Montenegro, **Peter Felten**

Sesija 5 / Session 5

14:30-16:00 Mijeloidne neoplazije: DGHO standardi

Myeloid disorders, DGHO Standards

Moderatori/Moderators: Nada Suvajdžić-Vuković, Nadežda Basara

14:30-15:00 Hartmut Döhner (Njemačka, Germany)

Akutna mijeloidna leukemija / Acute myeloid leukemia

15:00-15:30 Ahmet Elmaagacli (Njemačka/Germany)

*Mijelodisplastični sindrom, nova IPSS-M klasifikacija
Myelodysplastic syndrome, the new IPSS-M classification*

15:30-16:00 Tim Brümmendorf (Njemačka/Germany)

Hronične mijeloproliferativne neoplazije / Chronic myeloproliferative disorders

16:00-16:30 Kafe pauza / Coffee break

Sesija 6 / Session 6

16:30-18:30 Radijaciona onkologija- novine 2024

Radiation oncology- update 2024

Moderatori/Moderators: Vanja Karađinović, Marija Stolić

16:30-17:00 Aleksandar Čelebić / Mersid Ćorović (Crna Gora/Montenegro)

Lokoregiona terapija karcinoma dojke / Locoregional treatment of Breast Cancer

17:00-17:30 Tamara Ćulibrk (Srbija/Serbia)

Kako lečiti Karcinom pluća Stadijum III? / How to treat Lung cancer Stage III?

17:30-18:00 Mira Đurović (Crna Gora/Montenegro)

*Totalna neoadjuvantna terapija kod karcinoma rektuma: Up to date 2024
Total neoadjuvant therapy in rectal carcinoma: Up to date 2024*

18:00-18:30 Vanja Karađinović (Crna Gora/Montenegro)

Retretman kod Glioblastoma / Re-radiotherapy in glioblastoma

Sesija 7 / Session 7

18:30-19:30 Poster session:

Prezentacija postera / Poster presentations

Moderatori/Moderators: Nadežda Basara, Angela Krackhardt, Martin Reck

20:00 Svečana večera / Gala dinner

Dodjela nagrada najboljim posterima / Award ceremony for the best abstracts

Hotel Mediteran

Simposium / Symposium

08:40-09:00 Astra Zeneka

Danijela Agić, Dijana Šišević: Calquence (Acalabrutinib) u liječenju CLL

Simposium / Symposium

09:00-09:30 Takeda

Marija Stolić: 5-godišnje iskustvo sa Brigatinib kod ALK+NSCLC
5 year experience with Brigatinib in ALK+NSCLC

Ana Delić-Vukičević: Naše iskustvo sa Brigatinib kod ALK+NSCLC
The local experience with Brigatinib in front line ALK+NSCLC

Sesija 8 / Session 8

9:30-11:00 Najčešći carcinomi / The most common carcinoma

Moderatori/Moderators: Vladimir Kovčín, Marija Stolić

09:30-10:00 Claus-Henning Köhne (Njemačka/Germany)
Karcinom dojke / Breast Cancer

10:00-10:30 Carsten Bokemeyer (Njemačka/Germany)
Karcinom prostate / Prostate Cancer

10:30-11:00 Martin Reck (Njemačka/Germany)
Karcinom pluća / Lung Cancer

11:00-11:30 Kafe Pauza / Coffee break

Sesija 9 / Session 9

11:30-13:00 Vrlo česti solidni tumori / Very common solid tumors

Moderatori/Moderators: Carsten Bokemeyer, Sebastian Bauer

11:30-12:00 Christofer Gebhardt (Njemačka/Germany)
Maligni melanom / Malignant melanoma

12:00-12:30 Stefan Kasper-Virchow (Njemačka/Germany)
Kolorektalni karcinom / Colorectal cancer

12:30-13:00 Sebastian Bauer (Njemačka/Germany)
Sarkomi / Sarcoma

13:00-13:30 Ručak / Lunch

Simpozijum / Symposium

13:30-14:15 Johnson & Johnson

Milena Dapčević, Dijana Šišević:

The road to reshape life expectancy in CLL / Put koji mijenja životni vijek u HLL

Simpozijum / Symposium

14:15-14:45 **Servier**

Milan Sorat: *Sledeći koraci u kontinuitetu lečenja metastatskog kolorektalnog karcinoma*
The next steps in continuum of treatment for colorectal cancer

Sesija 10 / Session 10

14:45-15:45 **Interdisciplinarni Tumor Board / Interdisciplinary Tumor Board**

Sandra Krstajić, Miloš Bjelović, Marija Stolić, Tamara Ćulibrk, Mira Đurović, Dejan Perović
Moderatori/Moderators: Vladimir Kovčin, Vanja Karađinović

Sesija 11 / Session 11

15:45-16:45 **Uloga transfuziologa u TMČH / The role of transfusionist in HSCT**

Moderator: Tamara Šćepanović

15:45-16:05 **Tamara Šćepanović** (Crna Gora/Montenegro)

Kolekcija matičnih ćelija hematopoeze iz periferene krvi
Collection of hematopoietic stem cells from peripheral blood

16:05-16:25 **Angelina Cvijović-Ranitović** (Crna Gora/Montenegro)

Transfuziološka potpora kod ABO inkompatibilnih transplantacija matičnih ćelija hematopoeze
Transfusion support in ABO-incompatible hematopoiesis stem cell transplantation

16:25-16:45 **Jelena Zonjić** (Crna Gora/Montenegro)

Specifičnosti transfuzije krvnih komponentata kod transplantacije matičnih ćelija hematopoeze
Specificities of transfusion of blood components in hematopoietic stem cell transplantation

Sesija 12 / Session 12

16:45-17:00 **Zatvaranje kongresa / Closing Remarks**



www.telekomunikacija.rs



www.parfimerijatajna.rs

 @parfimerijatajna

FOR FIRST-LINE TREATMENT OF DLBCL

A clinical benefit full of life

Roche



reduced risk of progression, relapse, or death vs R-CHOP. That means more hope for the future, and more freedom from the threat of disease.



DLBCL – Diffuse large B-cell lymphoma, R-CHOP – rituximab, cyclophosphamide, doxorubicin, prednisone and vincristine
Sažetak karakteristika lijeka Polivy®, datum posljednje revizije: novembar, 2022.
SAMO ZA STRUČNU JAVNOST

▼Ovaj lijek je pod dodatnim praćenjem. Time se omogućava brzo otkrivanje novih bezbjednosnih informacija. Zdravstveni radnici treba da prijave svaku sumnju na neželjeno dejstvo ovog lijeka Institutu za lijekove i medicinska sredstva Crne Gore (CinMED). Za postupak prijavljivanja neželjenih reakcija na lijek posjetite <https://www.cinmed.me>. Nosilac dozvole: Hoffmann - La Roche LTD dio stranog društva Podgorica Cetinjska 11, 81000 Podgorica, Crna Gora+ 382 20 241 823.

Nosilac dozvole: Hoffmann-La Roche LTD dio stranog društva Podgorica Cetinjska 11, 81000 Podgorica, Crna Gora. Tel : + 382 20 241 823. Broj dozvole za stavljanje lijeka u promet: Polivy, 30mg,prašak za koncentrat za rastvor za infuziju: 2030/22/1888-2827; Polivy, 140mg, prašak za koncentrat za rastvor za infuziju: 2030/22/1885-2867; Datum prve dozvole za stavljanje lijeka u promet: 23.08.2022. godine. Datum revizije teksta SmPC: novembar, 2022. godine. Važna napomena: Prije propisivanja lijeka, detaljno proučiti u cijelosti Sažetak karakteristika lijeka. Režim izdavanja lijeka: ograničen recept. Cjelokupan sadržaj uživa autorsko-pravnu zaštitu © ROCHE 2024. Sadržaj ne smije biti kopiran, reprodukovana, distribuiran, objavljen, mijenjan, prenijeti ili prikazivan bez prethodne saglasnosti autora.

M-ME-00000970



Roche u ONKOLOGIJI



10  **Years** + **JAKAVI**[®]
ruxolitinib

The day you chose

JAKAVI

is the day you could

**CHANGE
THEIR LIFE**

MYELOFIBROSIS | POLYCYTHAEMIA VERA | GRAFT-VERSUS-HOST DISEASE

 **NOVARTIS**

Novartis Pharma Services AG
dio stranog društva Podgorica

ul. Svetlane Kane Radević br. 3, Podgorica, Crna Gora

 **JAKAVI**[®]
ruxolitinib

JAK PM No2 07/24 MNE - FA-11249078

imbruvica[®]
(ibrutinib)

LIVING AHEAD OF THE CURVE

with **IMBRUVICA**[®] 1-4

Because life is the
ultimate endpoint⁵⁻⁸

With over 8 years of follow-up,
IMBRUVICA[®] can provide 1L CLL
patients the chance of a **standardised
life expectancy**^{9*}

Johnson & Johnson
Innovative Medicine

1. Barr PM, et al. Up to 8 years follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. *Blood Adv.* 2022;6(11):3440-3450. 2. Dreyling M, et al. Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up. *Hemaglobin.* 2022;6(5):e712. 3. Buske C, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized Phase III INNOVATE study. *J Clin Oncol.* 2022;40(1):52-62. 4. Shanafelt TD, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. *Blood.* 2022;140(2):112-120. 5. Eichhorst B, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2021;32(1):23-33. 6. Delgado A, Guddati AK. Clinical endpoints in oncology-a primer. *Am J Cancer Res.* 2021;11(4):1121. 7. Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. *Cancer J.* 2009;15(5):401-405. 8. Le H, et al. Oncologist and patient preferences for novel agents in first-line treatment for chronic lymphocytic leukemia: commonalities and disconnects. *Patient Prefer Adher.* 2021;15:99-110. 9. Ghia P, et al. Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years. Poster presented at ASH 2022; 10-13 December 2022. #1809.

*OS data for IMBRUVICA[®]-treated patients with previously untreated CLL/SLL were pooled (n=603) from the RESONATE-2, E1912, and ILLUMINATE clinical studies (which evaluated IMBRUVICA[®] alone (n=136) or in combination with 6 cycles rituximab (n=354) or with 6 cycles obinutuzumab (n=113)/10, and compared with OS from an age-matched US general population (OS estimated from the CDC life table for total US population in 2019).⁹

Nosilac dozvole:
Glosarij doo
Vojislavljevića 76,
Podgorica, Crna Gora
CP-471755; 08/24

GLOSARIJ

VODEĆA VELEDROGERIJA U CRNOJ GORI

Više od tri decenije Glosarij zauzima leadersku poziciju u domenu snabdijevanja tržišta humanim lijekovima, medicinskim sredstvima i materijalima, kao i dijetetskim i kozmetičkim proizvodima. Za nama je preko trideset godina dosljednog i upornog razvoja vizije i saradnje sa preko 300 najpoznatijih regionalnih i svjetskih brendova koji se bave proizvodnjom lijekova i medicinske opreme

Kontakt:

- ☎ +382 20 642 495
- ✉ Ul. Vojslavljevića br. 76
81000 Podgorica
Crna Gora
- 🌐 www.glosarij.me





1. međunarodni KONGRES **ONKOLOGA** | **HEMATOLOGA**

1st international CONGRESS OF **ONCOLOGISTS** AND **HEMATOLOGISTS**

ZLATNI SPONZORI



SREBRNI SPONZORI

Johnson & Johnson



BRONZANI SPONZORI

